Literature DB >> 23891559

"Herbal incense": designer drug blends as cannabimimetics and their assessment by drug discrimination and other in vivo bioassays.

Torbjörn U C Järbe1, Roger S Gifford2.   

Abstract

Recently, synthetic cannabinoids originally designed for testing in the laboratory only have found use recreationally in designer herbal blends, originally called "Spice". The myriad of compounds found are for the most part potent full agonists of the cannabinoid receptor 1, producing effects similar to tetrahydrocannabinol (THC) and marijuana. Drug discrimination of these compounds offers a specific behavioral test that can help determine whether these new synthetic compounds share a similar "subjective high" with the effects of marijuana/THC. By utilization of drug discrimination and other behavioral techniques, a better understanding of these new "designer" cannabinoids may be reached to assist in treating both the acute and chronic effects of these drugs. The paper provides a brief exposé of modern cannabinoid research as a backdrop to the recreational use of designer herbal blend cannabimimetics.
© 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bioassays; Drug discrimination; Synthetic marijuana; THC

Mesh:

Substances:

Year:  2013        PMID: 23891559      PMCID: PMC4135441          DOI: 10.1016/j.lfs.2013.07.011

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  75 in total

1.  Discriminative stimulus effects of BAY 38-7271, a novel cannabinoid receptor agonist.

Authors:  Jean De Vry; Klaus Rüdiger Jentzsch
Journal:  Eur J Pharmacol       Date:  2002-12-20       Impact factor: 4.432

2.  AM2389, a high-affinity, in vivo potent CB1-receptor-selective cannabinergic ligand as evidenced by drug discrimination in rats and hypothermia testing in mice.

Authors:  Torbjörn U C Järbe; Sherrica Tai; Brian J LeMay; Spyros P Nikas; Vidyanand G Shukla; Alexander Zvonok; Alexandros Makriyannis
Journal:  Psychopharmacology (Berl)       Date:  2011-10-12       Impact factor: 4.530

3.  Novel 3-substituted rimonabant analogues lack Δ(9) -tetrahydrocannabinol-like abuse-related behavioural effects in mice.

Authors:  Dm Walentiny; Re Vann; A Mahadevan; R Kottani; R Gujjar; Jl Wiley
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

4.  Central mediation of the cannabinoid cue: activity of a selective CB1 antagonist, SR 141716A.

Authors:  A. Pério; M. Rinaldi-Carmona; J. Maruani; F. Barth; G. Le Fur; P. Soubrié
Journal:  Behav Pharmacol       Date:  1996-01       Impact factor: 2.293

5.  Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities.

Authors:  D R Compton; K C Rice; B R De Costa; R K Razdan; L S Melvin; M R Johnson; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1993-04       Impact factor: 4.030

6.  A comparison of the discriminative stimulus effects of delta(9)-tetrahydrocannabinol and O-1812, a potent and metabolically stable anandamide analog, in rats.

Authors:  Jenny L Wiley; Kari L LaVecchia; Natalie E Karp; Sanjitha Kulasegram; Anu Mahadevan; Raj K Razdan; Billy R Martin
Journal:  Exp Clin Psychopharmacol       Date:  2004-08       Impact factor: 3.157

7.  [Synthesis of (-)-delta6,1-3,4-trans-tetrahydrocannabinol, as well as (+)-delta 6,1-3,4-trans-tetrahydrocannabinol].

Authors:  T Petrzilka; C Sikemeier
Journal:  Helv Chim Acta       Date:  1967-07-10       Impact factor: 2.164

8.  Effects of the cannabinoid CB1 receptor antagonist SR141716A on the behavior of pigeons and rats.

Authors:  R S Mansbach; C C Rovetti; E N Winston; J A Lowe
Journal:  Psychopharmacology (Berl)       Date:  1996-04       Impact factor: 4.530

9.  Discriminative stimulus effects in rats of SR-141716 (rimonabant), a cannabinoid CB1 receptor antagonist.

Authors:  Torbjörn U C Järbe; Michele Y Harris; Chen Li; Qian Liu; Alexandros Makriyannis
Journal:  Psychopharmacology (Berl)       Date:  2004-05-27       Impact factor: 4.530

10.  Beyond THC: The New Generation of Cannabinoid Designer Drugs.

Authors:  Liana Fattore; Walter Fratta
Journal:  Front Behav Neurosci       Date:  2011-09-21       Impact factor: 3.558

View more
  5 in total

1.  Differentiation between low- and high-efficacy CB1 receptor agonists using a drug discrimination protocol for rats.

Authors:  Torbjörn U C Järbe; Brian J LeMay; Aneetha Halikhedkar; JodiAnne Wood; Subramanian K Vadivel; Alexander Zvonok; Alexandros Makriyannis
Journal:  Psychopharmacology (Berl)       Date:  2013-09-05       Impact factor: 4.530

2.  Finding order in chemical chaos - Continuing characterization of synthetic cannabinoid receptor agonists.

Authors:  Julie A Marusich; Jenny L Wiley; Timothy W Lefever; Purvi R Patel; Brian F Thomas
Journal:  Neuropharmacology       Date:  2017-11-04       Impact factor: 5.250

3.  The Changing Face of Recreational Drug Use.

Authors:  Michael H Baumann
Journal:  Cerebrum       Date:  2016-01-01

4.  Vaping Synthetic Cannabinoids: A Novel Preclinical Model of E-Cigarette Use in Mice.

Authors:  Timothy W Lefever; Julie A Marusich; Brian F Thomas; Daniel G Barrus; Nicholas C Peiper; Richard C Kevin; Jenny L Wiley
Journal:  Subst Abuse       Date:  2017-04-07

5.  Disruption of hippocampal synaptic transmission and long-term potentiation by psychoactive synthetic cannabinoid 'Spice' compounds: comparison with Δ9 -tetrahydrocannabinol.

Authors:  Alexander F Hoffman; Matthew D Lycas; Jakub R Kaczmarzyk; Charles E Spivak; Michael H Baumann; Carl R Lupica
Journal:  Addict Biol       Date:  2016-01-05       Impact factor: 4.280

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.